Share Icon Health Study Area: Cardiovascular Disease Chevron Icon Health Study Area: Genitourinary For Patients Health Study Area: Lung Cancer Page Icon Phone Icon For Caregivers Health Study Area: AutoImmune Disease Health Study Area: Melanoma Location Icon Print YouTube Icon For Parents Health Study Area: Lung Cancer Print Created with Sketch. Help Icon Green Check Icon Search Icon Instagram Created with sketchtool. Direction Arrow Icon Error Icon For Parents Health Study Area: Blood Cancer Help Icon Health Study Area: NASH Gender Both Bookmark Icon Health Study Area: Melanoma Created with Sketch. Glossary Print Health Study Area: Blood Cancer Health Study Area: Genitourinary Health Study Area: Gastrointestinal Cancer Mobile Menu Icon Created with Sketch. Health Study Area: Cardiovascular Disease Health Study Area: Women's Cancer Communities Map Icon Created with Sketch. For Caregivers Health Study Area: Fibrosis Health Study Area: AutoImmune Disease FAQs Health Study Area: Head and Neck Cancer Created with Sketch. For Clinicians Chevron Right Icon Gender Female Health Study Area: Breast Cancer Direction Arrow Icon Gender Both Right Arrow Icon LinkedIn Icon Green Check Icon Gender Male Health Study Area: Fibrosis For Patients Twitter Icon Email Icon Facebook Icon Health Study Area: Gastrointestinal Cancer Health Study Area: Head and Neck Cancer For Clinicians External Link Icon

Menu

Search BMS Clinical Trials
BMS Recruiting Study icon

Recruiting

Trial ID CA209-67T  |   NCT04810078

A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread

Summary

  • Phase 3
  • Male and Female Gender icon
  • 18+
    Age Range
  • 20
    Locations
  • BMS Recruiting Study icon
    Recruiting

Overview

The purpose of this study is to evaluate the drug levels, efficacy, safety, and tolerability of subcutaneous nivolumab versus intravenous nivolumab in participants with previously treated clear cell renal cell carcinoma that is advanced or has spread. The purpose of this study's substudy is to evaluate drug level biocomparability of subcutaneous nivolumab manufactured using two different manufacturing processes.

print Print
email Email

Nearest Recruiting Site

Key Eligibility Criteria

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria

Inclusion Criteria Icon img
:
  • Histological confirmation of renal cell carcinoma (RCC) with a clear cell component, including participants who may also have sarcomatoid features
    1. Advanced RCC (not amenable to curative surgery or radiation therapy) or metastatic RCC (Stage IV)
      1. Measurable disease as defined by Response Evaluation Criteria in Solid Tumor (RECIST) v1.1 criteria within 28 days prior to randomization
        1. Received no more than 2 prior systemic treatment regimens
          1. Intolerance or progression on or after the last treatment regimen received and within 6 months prior to randomization
            1. Karnofsky PS ≥ 70 at screening
              1. Must agree to follow specific methods of contraception, if applicable

                Exclusion Criteria

                Exclusion Criteria Icon
                :
                • Untreated, symptomatic central nervous system (CNS) metastases
                  1. Concurrent malignancy (present during screening) requiring treatment or history of prior malignancy active within 2 years prior to randomization
                    1. Active, known, or suspected autoimmune disease
                      1. Known human immunodeficiency virus (HIV) positive with an acquired immunodeficiency syndrome (AIDS) defining opportunistic infection within the last year, or a current CD4 count < 350 cells/μL. Participants with HIV are eligible if: 1. They have received established antiretroviral therapy (ART) for at least 4 weeks prior to randomization 2. They continue on ART as clinically indicated while enrolled on study 3. CD4 counts and viral load are monitored per standard of care by a local health care provider 4. Inclusion of participants with HIV should be based on Investigator clinical judgment in consultation with the Medical Monitor NOTE: Testing for HIV must be performed at sites where mandated locally. HIV-positive participants must be excluded where mandated locally
                        1. Serious or uncontrolled medical disorders including for example, active severe acute respiratory syndrome coronavirus 2 (SAR-CoV-2) infection within approximately 4 weeks prior to screening. In the case of prior SARS-CoV-2 infection, acute symptoms must have resolved based on investigator clinical judgment and, in consultation with Medical Monitor, there are no sequelae that would place the participant at a higher risk of receiving investigational treatment to be eligible
                          1. Prior treatment with an programmed death receptor-1 (anti-PD-1), programmed death ligand-1 (anti-PD-L1), or cytotoxic T-lymphocyte-associated antigen-4 (anti-CTLA-4) antibody, or any other antibody or drug specifically targeting T-cell costimulation or checkpoint pathways
                            1. Treatment with any live attenuated vaccine within 30 days of first study treatment Other protocol-defined inclusion/exclusion criteria apply
                              Additional Information *

                              Treatment Options

                              Study Arms

                              ASSIGNED INTERVENTION

                              Study Arms

                              Experimental: Arm A

                              ASSIGNED INTERVENTION
                              • Biological: Nivolumab and rHuPH20

                              Study Arms

                              Active Comparator: Arm B

                              ASSIGNED INTERVENTION
                              • Biological: Nivolumab

                              Study Arms

                              Experimental: Arm C

                              ASSIGNED INTERVENTION
                              • Biological: Nivolumab and rHuPH20

                              Study Arms

                              Experimental: Arm D

                              ASSIGNED INTERVENTION
                              • Biological: Nivolumab and rHuPH20
                              Take the first step to see if you Match to a Clinical Trial – Check if you qualify
                              Check if you qualify
                              Answer some questions about Your health to see if you may match to this trial
                              Match to a Trial
                              If you are a match, click on the study to see the list of study site locations
                              Select a Study Site Location
                              Select a study site location that is convenient for you
                              Register
                              Provide your contact details for the study site to connect with you.

                              Help us enhance your website experience! Share your feedback with our team at BMS Clinical Trials to improve yours and others’ experience. Thank you